PEN vs SYRE
Penumbra, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
PEN
Penumbra, Inc.
67
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | PEN | SYRE |
|---|
| AI Score |
67
|
67
|
| Price |
$326.07
|
$102.72
|
| P/E Ratio |
79.78×
|
-52.69×
|
| ROE |
12.4%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.8%
|
0.0%
|
| Debt / Equity |
0.14×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.6
|
53.3
|
| Beta |
0.701
|
3.026
|
| Expected Upside |
+6.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for PEN versus SYRE.
The committee scores are tied.
PEN and SYRE both score 67/100.
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical